KLA Corp: Mixed Bag - 2027 Outlook Raised but 2026 Underperformance Persists

Core Conclusion

KLA's March quarter and June guidance modestly exceeded consensus, yet the print reinforced a split narrative: 2026 growth lags process peers due to mix headwinds, while the 2027 outlook was revised upward more sharply than expected. We view 2026 underperformance as well understood and already discounted. The incremental data points—supply chain readiness, advanced packaging strength, and explicit 2027 acceleration language—strengthen the bull case. Maintain Overweight, target raised to $1,900.

What the Market May Be Underpricing

The focus on KLA's 2026 peer-relative deceleration (TSMC 3nm capacity adds with lower process-control intensity, DRAM upgrades vs. greenfield) risks obscuring the 2027 inflection. KLA revised its 2027 language from "growth rate similar or higher than CY26" to "higher than our growth rate expectations for 2026". Management cited a "huge amount of interest" for slot assignments, underscoring visibility from near-monopoly tools with 11-12 month lead times. The 2027 revenue growth forecast was raised from 22.7% to 23.7%.

Evidence Chain

1. 2026 underperformance is structural but expected. KLA raised its 2026 WFE outlook from $135-140bn to $140bn+, in line with peers. However, the mix of 3nm adds (TSMC) and DRAM upgrades depresses KLA's relative growth. Supply constraints in 1H limit full-year revenue upgrades. No new reasons to change the 2026 view.

2. 2027 outlook upgraded on demand and supply confidence. Drivers remain 1.4nm logic, Intel foundry, 1c/1d DRAM transitions, and hybrid bonding in HBM. Over the past nine months KLA improved supply chain capacity to support $180bn+ WFE. Advanced packaging process-control revenue forecast raised to $1.3-1.4bn (57% y/y from $925mn in 2025), countering bear narratives of share loss.

3. Estimate revisions reflect operating leverage. CY26 EPS raised from $42.77 to $43.84, CY27 from $54.81 to $57.58. Operating margin assumptions increased from 43.8% to 44.4% (CY26) and from 45.0% to 46.4% (CY27), driven by higher revenue and improved cost leverage.

Key Divergences and Risks

• Bull case: 2026 underperformance is priced; 2027 inflections provide upside. KLA's longer lead times and near-monopoly in mask/e-beam give it first-mover advantage. Advanced packaging guidance dissipates share-loss fears.
• Bear case: 2026 relative weakness persists for the full year; market share loss to Lasertec (mask inspection) or AMAT/ASML (e-beam) could accelerate. China restrictions and Intel Foundry scaling back remain tail risks.
• Primary risks: Foundry (Intel, Samsung) capex cuts, China export controls, competitive displacement in mask inspection.

Valuation and Trading Implications

Our price target moves to $1,900 (from $1,809), applying 33x CY27e EPS of $57.58—a 15% premium to AMAT/LAM—justified by KLA's superior growth profile and gross margin. Bull case $2,334 (36x, strong market share gains); bear case $1,367 (26x, share contraction). Upside from current $1,816 is +4.6%. We recommend overweight positioning for 2027 catalysts; near-term peer underperformance is a headwind but should dissipate as narrative shifts.

Appendix: Key Estimate Changes